Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Franklin Resources Inc.

Franklin Resources Inc. lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,896,086 shares of the biopharmaceutical company’s stock after selling 27,016 shares during the quarter. Franklin Resources Inc. owned approximately 1.73% of Regeneron Pharmaceuticals worth $1,912,695,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Rakuten Securities Inc. raised its stake in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares in the last quarter. Stephens Consulting LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $26,000. Sachetta LLC lifted its stake in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the last quarter. FSA Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter worth $26,000. Finally, Family Firm Inc. bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at $33,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $740.97 on Friday. The business has a 50 day moving average price of $855.40 and a two-hundred day moving average price of $1,005.56. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company has a market capitalization of $81.43 billion, a price-to-earnings ratio of 18.34, a price-to-earnings-growth ratio of 2.32 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 1-year low of $735.95 and a 1-year high of $1,211.20.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Morgan Stanley decreased their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Wells Fargo & Company lowered their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, October 22nd. Finally, Leerink Partnrs cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $1,099.90.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.